Cargando…
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma
Harnessing the immune system with immune-checkpoint(s) blockade (ICB) has dramatically changed the treatment landscape of advanced melanoma patients in the last decade. Indeed, durable clinical responses and long-term survival can be achieved with anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and a...
Autores principales: | Simonetti, Elena, Cutarella, Serena, Valente, Monica, Sani, Tommaso, Ravara, Matteo, Maio, Michele, Di Giacomo, Anna Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083011/ https://www.ncbi.nlm.nih.gov/pubmed/37041860 http://dx.doi.org/10.2147/OTT.S368408 |
Ejemplares similares
-
Immunotherapy of brain metastases: breaking a “dogma”
por: Di Giacomo, Anna Maria, et al.
Publicado: (2019) -
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop”
por: Colucci, Maura, et al.
Publicado: (2022) -
Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022) -
How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma
por: Martini, Giulia, et al.
Publicado: (2021) -
Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
por: Kaufman, Howard L, et al.
Publicado: (2014)